经济观察网讯 5月6日重点关注的财经要闻与资本市场大事： （原标题：今日看点｜北交所为试点股票启用新证券代码） 5月6日，21家公司共发布21个股票回购相关进展。其中，2家公司首次披露股票回购预案，14家公司披 露股票回购实施进展，5家公司回购方案已实施完毕。 从首次披露回购预案来看，当日共1家公司股票回购预案金额超千万。科思科技、毅昌科技回购预案金 额最高，分别拟回购不超5000.0万元、66.36万元。从回购实施进展来看，美的集团、长春高新、九安医 疗回购金额最高，分别回购5.54亿元、4.0亿元、3.7亿元。从已完成回购来看，当日共4家公司回购金额 超千万。华工科技、天茂集团、万邦德已完成回购金额最高，分别回购3.95亿元、9998.26万元、 5998.85万元。 4、美国3月贸易帐、欧元区3月PPI月率等数据将公布。 （数据来源Wind，内容不构成任何投资建议） 1、北交所为试点股票启用新证券代码 近日，北交所发布通知，北交所存量上市公司代码切换试点工作总体准备就绪，拟于2025年5月6日正式 上线。根据通知，2025年5月1日至2025年5月5日期间，北交所组织开展代码切换与通关测试，自2025年 ...

证券代码：000661 证券简称：长春高新 公告编号：2025-047 上述回购符合相关法律、法规的规定及A股回购方案的要求。 二、其他说明 公司回购股份的时间、数量、价格及集中竞价交易的委托时段符合《深圳 证券交易所上市公司自律监管指引第9号——回购股份》第十七条和第十八条的 相关规定。具体说明如下： 长春高新技术产业（集团）股份有限公司 关于回购股份进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 长春高新技术产业（集团）股份有限公司（以下简称"公司"）于2024年 11月14日召开了第十一届董事会第六次会议，审议通过了《关于公司回购股份 方案的议案》，同意公司使用自有资金及金融机构股票回购专项贷款资金以集 中竞价交易方式回购部分公司已在境内发行的人民币普通股（A股）股票，全 部用于后续实施公司及子公司核心团队股权激励或员工持股计划。拟用于回购 资金总额不低于人民币3亿元（含）、不超过人民币5亿元（含），回购价格不 超过人民币160.00元/股。具体回购股份数量以回购期限届满时实际回购的股份 数量为准。 上述内容详见公司于2024年11月16 ...

Group 1 - The Shanghai Composite Index opened lower and the CSI 300 Pharmaceutical and Biotechnology Index reported 7459.13 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 3.80% over the past month, increased by 3.37% over the past three months, and has risen by 0.20% year-to-date [1] - The CSI 300 Index categorizes its 300 sample stocks into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten holdings in the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (24.67%), WuXi AppTec (16.06%), Pian Zai Huang (6.84%), Yunnan Baiyao (5.71%), Kelun Pharmaceutical (4.69%), New Horizon (3.81%), East China Pharmaceutical (3.6%), Shanghai Raist (3.44%), Fosun Pharma (3.37%), and Changchun High-tech (3.18%) [1] - The market share of the CSI 300 Pharmaceutical and Biotechnology Index is 63.43% from the Shanghai Stock Exchange and 36.57% from the Shenzhen Stock Exchange [2] - The industry composition of the index includes: chemical drugs (42.67%), pharmaceutical and biotechnology services (21.27%), traditional Chinese medicine (19.68%), and biological drugs (16.38%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted along with the sample adjustments, which are generally fixed until the next scheduled adjustment [2] - Temporary adjustments occur when the CSI 300 Index samples are modified, and changes in industry classification due to special events will also lead to corresponding adjustments in the CSI 300 industry index [2]

Policy Developments - The National Medical Products Administration (NMPA) released the "Quality Management Specifications for Online Sales of Medical Devices," effective from October 1, 2025, which emphasizes qualification review, information transparency, and risk prevention for online medical device sales [1] Drug and Device Approvals - Insilico Medicine's INS018_055 tablet is expected to receive breakthrough therapy designation for treating idiopathic pulmonary fibrosis [2] - Yuyuan Pharmaceutical's injectable Ganciclovir has passed the consistency evaluation for generic drugs, which will enhance the company's market share and competitiveness [3] - Warner Pharmaceuticals' Bismuth Potassium Citrate Granules have also passed the consistency evaluation for generic drugs, benefiting future market sales [4] - Changchun High-tech's subsidiary, Jinsai Pharmaceutical, received approval for clinical trials of Fuxin Qibai monoclonal antibody injection, aimed at treating endometriosis [5] Financial Reports - Yunnan Baiyao reported a Q1 2025 net profit of 1.935 billion yuan, a 13.67% increase year-on-year, with total revenue of 10.841 billion yuan, up 0.62% [6] - WuXi AppTec's Q1 2025 net profit surged by 89.06% to 3.672 billion yuan, driven by revenue growth and operational efficiency improvements [7][8] - Kefu Medical's 2024 annual report showed a net profit increase of 22.6% to 312 million yuan, with revenue of 2.983 billion yuan, up 4.53% [9] - Hongbo Pharmaceutical's Q1 2025 net profit increased by 226.47% to 11.974 million yuan, with revenue of 16.9 million yuan, up 29.61% [10] Capital Market Activities - Jiangsu Hengrui Medicine has received approval from the China Securities Regulatory Commission for its Hong Kong IPO, planning to issue up to 815.1 million shares [11] - Merck announced its acquisition of SpringWorks for approximately $3.9 billion in equity value [12] - China Merchants Bio intends to increase its stake in Renfu Pharmaceutical by 0.5%-1% within six months, reflecting confidence in the company's future [13] Industry Developments - Xiangyu Medical expects to obtain registration certificates for seven robotic products by 2025, focusing on rehabilitation and other medical applications [14] - Soundon Medical has formed a strategic partnership with MED-EL's BHM to advance global bone conduction hearing solutions [16] - Hanyu Pharmaceutical signed a comprehensive cooperation agreement with Huawei Cloud to focus on "AI Smart Drugs" in drug development [17] Public Sentiment Alerts - Innovative Medical announced that shareholder Shanghai Guanghuan Technology reduced its stake by 3.41 million shares, representing 0.8191% of the total circulating shares [18]

Core Viewpoint - Changchun High-tech (000661) held an investor conference after releasing its 2024 annual report, highlighting its focus on R&D innovation and the progress of multiple drug pipelines, particularly in the fields of women's and children's health [1][2]. Financial Performance - The company invested nearly 2.7 billion yuan in R&D in 2024, sacrificing short-term performance for long-term growth [1]. - The 2024 annual report indicated that the company's performance was not outstanding, but the results of increased R&D investment in recent years are noteworthy [1]. Product Pipeline - Five major products from the core subsidiary, Jinsai Pharmaceutical, were approved for market launch in early 2024, including: - Recombinant human follicle-stimulating hormone injection (Jinsai Heng) - Acetate medroxyprogesterone oral suspension (Meishiya) - Progesterone injection (II) (Jinsai Xin) - Oral gel (Yipushu) - Innovative traditional Chinese medicine pediatric cough granules (Jinsai Ke) [1]. Clinical Trials and Innovations - The company showcased several promising drug candidates during the investor call, including: - Vuxin Qibai monoclonal antibody, which is expected to be the first IL-1β monoclonal antibody approved in China for adult gouty arthritis, showing significant efficacy and safety in clinical trials [2]. - GS1-144 tablets, a novel NK3R small molecule antagonist for menopausal vasomotor symptoms, currently in phase II clinical trials domestically and phase I in Australia [2]. - GenSci120 injection, a humanized anti-PD-1 monoclonal antibody for systemic lupus erythematosus and other autoimmune diseases, with IND approvals expected in early 2025 [3]. Strategic Focus - The company is actively advancing its R&D efforts across various therapeutic areas, including women's and children's health, metabolism, autoimmune diseases, oncology, vaccines, and traditional Chinese medicine, aiming to reduce reliance on single products [4].

证券代码：000661 证券简称：长春高新 公告编号：2025-046 一、药品的基本情况 产品名称：伏欣奇拜单抗注射液 申请事项：境内生产药品注册临床试验 受理号：CXSL2500163 申请人：长春金赛药业有限责任公司 审批结论：经审查，同意本品开展临床试验 适应症：子宫内膜异位症 二、药品的其它情况 伏欣奇拜单抗注射液是金赛药业自主研发的治疗用生物制品 1 类新药，拟用 于子宫内膜异位症。子宫内膜异位症是一种常见的慢性系统性炎症性疾病，发病 率约 10%-15%，且易复发，需长期管理。伏欣奇拜单抗能够特异性阻断 IL-1β与 受体 IL-1R 的结合，从而阻断受体激活引起的下游信号通路的活化，起到治疗子 宫内膜异位症的作用，已在临床前动物模型中展现了良好的疗效。本次临床试验 申请获批可推动后续该产品临床开发并进一步满足患者的临床需求。 2025 年 1 月，伏欣奇拜单抗注射液拟用于成年痛风性关节炎急性发作患者 的上市申请已获得国家药品监督管理局受理。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网披露的《关于伏欣奇拜单抗注射液上市申请获得受理的公告》 （公告编号 2025-010）。 1 ...

Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Jinsai Pharmaceutical, received approval from the National Medical Products Administration for the clinical trial application of Fuxin Qibai monoclonal antibody injection, which is a first-class new drug for the treatment of endometriosis [1] Company Summary - Jinsai Pharmaceutical is developing Fuxin Qibai monoclonal antibody injection, which is a self-developed biological product aimed at treating endometriosis [1] - The drug specifically blocks the binding of IL-1β to its receptor IL-1R, thereby inhibiting the activation of downstream signaling pathways associated with the receptor [1] - The approval of the clinical trial application will facilitate the subsequent clinical development of this product and further meet the clinical needs of patients [1] Industry Summary - Endometriosis is a common chronic systemic inflammatory disease with an incidence rate of approximately 10%-15% and is prone to recurrence, requiring long-term management [1] - The successful development of new treatments like Fuxin Qibai monoclonal antibody injection could significantly impact the management of endometriosis and improve patient outcomes [1]

Core Points - The Shanghai Composite Index opened lower and the CSI 300 Pharmaceutical and Biotechnology Index reported 7479.61 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 0.64% in the past month, increased by 3.66% over the last three months, and has risen by 0.48% year-to-date [1] Industry Composition - The CSI 300 Pharmaceutical and Biotechnology Index is composed of 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] - The index is based on the performance of all securities in the CSI 300 Index classified by industry, with a base date of December 31, 2004, and a base point of 1000.0 [1] Index Holdings - The top ten holdings in the CSI 300 Pharmaceutical and Biotechnology Index are: - Heng Rui Medicine (24.75%) - WuXi AppTec (15.82%) - Pian Zai Huang (6.85%) - Yunnan Baiyao (5.7%) - Kelun Pharmaceutical (4.68%) - New Horizon (3.79%) - East China Pharmaceutical (3.64%) - Shanghai Raist (3.44%) - Fosun Pharma (3.38%) - Changchun High-tech (3.17%) [1] Market Distribution - The market distribution of the CSI 300 Pharmaceutical and Biotechnology Index shows that the Shanghai Stock Exchange accounts for 63.33% and the Shenzhen Stock Exchange accounts for 36.67% [2] Sector Breakdown - The sector breakdown of the index holdings indicates that: - Chemical drugs account for 42.69% - Pharmaceutical and biotechnology services account for 21.06% - Traditional Chinese medicine accounts for 19.74% - Biological drugs account for 16.51% [2] Sample Adjustment - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with sample changes, and any special events affecting a sample company's industry classification will lead to corresponding adjustments in the index [2]

Group 1 - Multiple banks have issued warnings about the risks of gold investment, particularly regarding the use of credit cards for purchasing gold, which is considered a violation of regulations [1] - The "Guzi" economy, centered around anime and gaming merchandise, is projected to reach a market size of 168.9 billion yuan in 2024, reflecting a growth of 40.63% from 2023 [1] - The first public appearance of a megawatt-level helium refrigeration machine marks a significant breakthrough in China's low-temperature technology, with a liquefaction rate of 3,370 liters per hour [1] Group 2 - The first embodied intelligent robot sports event in Wuxi showcased advancements in robotics, with local companies making progress in key technologies [2] - MIT has created a unique "periodic table" of machine learning algorithms, highlighting over 20 classic algorithms and their interconnections, which may enhance AI model development [2] - Harvard University is exploring the sale of approximately $1 billion in private equity fund assets as part of a financial strategy following a federal funding freeze [2] Group 3 - Meituan clarified rumors regarding account suspensions due to alleged use of dual-opening or JD software, attributing the misinformation to malicious editing of a legitimate warning [3][4] - Tianhe Environmental Protection has terminated its IPO plans on the Beijing Stock Exchange, which aimed to raise 180 million yuan for various projects [4] - The first quarter performance report of several futures companies indicates a significant divergence in results, with some companies experiencing substantial growth while others face declines [5] Group 4 - Tianli Lithium Energy announced that its subsidiary's land use rights have been seized due to a lawsuit, with a three-year freeze period [6] - Ningbo Shuntong received a written warning from the Shanghai Stock Exchange for inaccuracies in its financial data disclosures [6] - Rixin Technology reported overdue bank loans totaling 39.7 million yuan, and is in discussions with the bank to secure funds for repayment [7] Group 5 - A private education institution from Chengdu has emerged in the A-share market, acquiring significant stakes in multiple companies, with total holdings exceeding 55 million yuan [8] - Changchun High-tech reported its first decline in revenue and net profit in a decade, with a 7.55% drop in revenue to 13.466 billion yuan and a 43.01% decrease in net profit to 2.583 billion yuan [8]

以下文章来源于36氪Pro ，作者胡香赟 海若镜 36氪Pro . 文 ｜ 胡香赟 编辑 ｜ 海若镜 来源｜ 36氪Pro（ID：krkrpro） 封面来源 ｜ Pexels 我想"再高一点" 春日，宜万物生长，包括人类幼崽的身高。 在讲究科学的时代，孩子的身高理所应当地也应遵循某种可量化的生长公式。 一个颇受大众认可的方法是，根据父母身高来预测孩子未来的身高区间。比如，男孩子的身高区间=（父亲身高+母亲身高+13厘米）÷2±7.5厘米。 公式前半部分就是所谓的"遗传靶身高"，即由遗传决定的无法改变的身高基数。而后半部分的"±7.5厘米"，则是可以通过后天努力改变的部分——只需 要"充分发挥孩子的生长潜能"。 梁宇在一家药企从事研发工作，出于职业敏感，女儿萱萱还在上幼儿园时，就开始关注她的身高问题。她坦言自己和先生都不算高，对孩子未来的身 高"没有过大期待，她个子不高，这点从小就能看出来"。 尽管如此，萱萱上大班后，梁宇还是开始给她报了跳绳兴趣班。运动、光照、补充维生素D，最初梁宇选择的是最朴素的科学"长个儿"方法。 36氪旗下官方账号。深度、前瞻，为1%的人捕捉商业先机。 如果可以，谁都希望自己的孩子 是人 ...